Ionis Pharmaceuticals (IONS) Misses Q1 EPS by 23c
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.35), $0.23 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $133 million versus the consensus estimate of $161.13 million.
- On track to achieve 2020 financial guidance
- "We are reaffirming our 2020 financial guidance, including ending 2020 meaningfully profitable. We expect our results to be driven by continued significant commercial revenue and R&D revenue from numerous programs," said Elizabeth L. Hougen, chief financial officer of Ionis. "We remain well-capitalized, with a strong balance sheet and $2.4 billion in cash and investments. Enabled by our financial strength, we have the resources to execute on our near- and longer-term strategic priorities, even in the challenging COVID-19 pandemic environment."
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
- The Shyft Group (SHYF) Tops Q1 EPS by 10c ; Offers Guidance
- Lakeland Financial (LKFN) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!